4.5 Article

Predictors of Institutionalization in Dementia: A Three Year Longitudinal Study

Journal

JOURNAL OF ALZHEIMERS DISEASE
Volume 40, Issue 1, Pages 221-226

Publisher

IOS PRESS
DOI: 10.3233/JAD-131850

Keywords

Alzheimer's disease; dementia; institutionalization; longitudinal; nursing home; survival analysis

Categories

Funding

  1. National Health and Medical Research Council
  2. Janssen-Cilag Pty Limited
  3. Eisai Pharmaceuticals
  4. Eli Lilly and Company
  5. GlaxoSmithKline
  6. H Lundbeck A/S
  7. Medivation Inc.
  8. Novartis Pharmaceuticals
  9. Nutricia
  10. Pfizer Inc.
  11. Prana Biotechnology Limited
  12. Sanofi-Aventis
  13. Tau Rx
  14. Voyager Pharmaceutical Corporation
  15. Wyeth Limited
  16. Servier
  17. Forest
  18. Takeda
  19. Buck Institute
  20. Baxter
  21. bioCSL
  22. Prana Biotechnology
  23. Merck Sharp and Dohme
  24. Lundbeck
  25. Prana
  26. Pfizer
  27. Novartis

Ask authors/readers for more resources

Patients with dementia often require institutionalization when they can no longer care for themselves. The study examined demographic and clinical variables that predict the time until institutionalization in patients with dementia attending memory clinics. Of 970 patients recruited from nine memory clinics around Australia, 779 patients had dementia at baseline. Measures of dementia severity, cognition, functional ability, neuropsychiatric symptoms, caregiver burden, and medication use were completed for all patients. Patients were followed for three years. Overall, 197 (25.3%) of the patients with dementia were institutionalized within three years. Lower cognitive ability, lower functional ability, and more neuropsychiatric symptoms at baseline predicted a shorter time until institutionalization, as did use of antipsychotic medication. In addition, greater deterioration in cognitive ability, functional ability, and neuropsychiatric symptoms over the initial three months predicted a shorter time to institutionalization. The findings confirm that clinical features of dementia at baseline predict the time to institutionalization, as do greater changes in symptoms over three months independent of baseline levels.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available